- TRADE NAME: Recarbrio (MSD)
- INDICATIONS: Patients 18 years of age and older who have limited, or no alternative treatment options, for the treatment of the following infections caused by susceptible gram-negative bacteria: complicated urinary tract infections, including pyelonephritis; complicated intra-abdominal infections
- CLASS: Antibiotic, Antibiotic; carbapenem (imipenem), Antimicrobial, Beta-lactamase inhibitor (relebactam), Renal dehydropeptidase inhibitor (cilastatin)
- HALF-LIFE: 1 hour (imipenem); 1.2 hours (relebactam); 1 hour (cilastatin)
- FDA APPROVAL DATE: 07/16/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Ganciclovir, Valproic Acid - PREGNANCY: Insufficient human data to establish whether there is a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes with imipenem, cilastatin, or relebactam in pregnant women.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023